Inpixon
NASDAQ:XTIA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Inpixon
NASDAQ:XTIA
|
US |
|
P
|
Prabos Plus as
PSE:PRAB
|
CZ |
|
D
|
Dexcom Inc
F:DC4
|
US |
|
Alteogen Inc
KOSDAQ:196170
|
KR |
|
HOOKIPA Pharma Inc
NASDAQ:HOOK
|
US |
|
P
|
Phol Dhanya PCL
SET:PHOL
|
TH |
|
V
|
Viserve Enterprise PCL
SET:VS
|
TH |
Wall St Price Targets
XTIA Price Targets Summary
Inpixon
According to Wall Street analysts, the average 1-year price target for
XTIA is 5.1 USD with a low forecast of 5.05 USD and a high forecast of 5.25 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is XTIA's stock price target?
Price Target
5.1
USD
According to Wall Street analysts, the average 1-year price target for
XTIA is 5.1 USD with a low forecast of 5.05 USD and a high forecast of 5.25 USD.
What is the Revenue forecast for Inpixon?
Projected CAGR
190%
Over the last 13 years, the compound annual growth rate for Revenue has been 14%. The projected CAGR for the next 2 years is 190%.
What is the Gross Profit forecast for Inpixon?
Projected CAGR
181%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 8%. The projected CAGR for the next 2 years is 181%.